Search Results

Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”) announced today it has been selected to exhibit the Aurix® System, the first platelet rich plasma (PRP) device indicated for chronic diabetic wounds, at the Vizient Innovative Technology Exchange.

Nuo Therapeutics, Inc., a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage, the nation’s leading wound care consulting firm has added the Aurix® System to its formulary.

Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo” or the “Company”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced today an initial corporate and business update since re-establishing fully available commercial operations in the second quarter of this year.

Nuo Therapeutics, Inc. (“Nuo” or the “Company”) announced that it is aware of an unsolicited “mini-tender” offer by Alternative Liquidity Index, LP to purchase up to 1,820,000 shares of Nuo common stock, approximately 4.9% of the outstanding shares, at $0.01 per share.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Nuo Therapeutics, Inc. (OTC Pink: AURX) (“Nuo” or the “Company”), today announced the closing of a recapitalization and exchange agreement between the Company, Deerfield Management and affiliates thereof (Deerfield Investors), and senior secured noteholders (Noteholders) whereby the Series A Preferred Stock held by the Deerfield Investor

Nuo Therapeutics, Inc. (OTC Pink: AURX) (“Nuo” or the “Company”), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). On April 13, 2021 , Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.